For over 30 years our companies have made treating complex and life-threatening conditions possible, supporting clinicians, healthcare systems and governments while offering hope to patients and their families.
Acquired the rights to Xermelo outside the US and Japan from Ipsen.
BTG begins directly selling its own products in the US.
BTG Plc acquired Protherics plc, a developer of new immunotherapeutic products and therapies.
DIGIFab® (digoxin immune Fab (ovine)) launched in the US.
CroFab® (crotalidae polyvalent immune fab (ovine)) launched in the US.
Special Products Ltd (later Veriton Pharma) founded by Dr Graham March, a pharmacist with experience working at Great Ormond Street Hospital, and at major pharmaceutical companies. The company focused on unlicensed medicines for patients with special requirements.
BTG (British Technology Group) is formed by the British government from the merger of the National Research & Development Council and the National Enterprise Board. The group is later privatised (1992) and listed on the London Stock exchange (1995).
SERB (Société d’Études et de Recherches Biologiques) is created in Paris.
You are leaving the SERB.com global corporate website